Allogene Therapeutics (ALLO) Tax Provisions (2018 - 2019)
Allogene Therapeutics (ALLO) reported Tax Provisions of -$131000.0 for Q4 2019, down 11.97% on a YoY basis from -$148805.8 in Q4 2018, and up 34.5% sequentially from -$200000.0 in Q2 2019.
Allogene Therapeutics (ALLO) Tax Provisions (2018 - 2019) Analysis & Trends
Allogene Therapeutics (ALLO) has 2 years of Tax Provisions data on file, last reported at -$131000.0 in Q4 2019.
- For the quarter ending Q4 2019, Tax Provisions fell 11.97% year-over-year to -$131000.0; the trailing twelve-month figure through Sep 2020 stood at -$131000.0 (up 64.31% YoY), and the FY2024 full-year result was $443000.0, changed N/A from the prior year.
- Tax Provisions advanced to -$131000.0 in Q4 2019, from -$200000.0 in the prior quarter.
- In the past five years, Tax Provisions ranged from a high of -$50000.0 in Q1 2019 to a low of -$200000.0 in Q2 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 125,146.46 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 31.86 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 188,883.60 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 221.50 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 104.00 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 179.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Allogene Therapeutics | 437.33 Mn | 437.33 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2019 | -131,000.00 |
| Jun 30, 2019 | -200,000.00 |
| Mar 31, 2019 | -50,000.00 |
| Dec 31, 2018 | -117,000.00 |